You are here: Industry Insights > chronic kidney disease

News List

Pharmaceutical News of the Week | CPhI.CN - R&D PharmaSources/Caicai
August 06, 2020
Clinical trials were approved for recombinant human papillomavirus 9-valent vaccine (Pichia pastoris) and recombinant herpes zoster vaccine (CHO) jointly applied for by Shanghai Easyway and Ab&b Bio-Tech on July 27.
NICE recommends AstraZeneca’s dapagliflozin to treat chronic kidney disease Pharmaceutical-Business-Review
November 09, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s dapagliflozin as a treatment for people with chronic kidney disease (CKD).
FDA Approves Kerendia (finerenone) for the Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes drugs
July 12, 2021
Bayer announced today the FDA has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death.
Bayer's finerenone hits targets in diabetes/kidney disease trial pharmatimes
July 14, 2020
Bayer's finerenone has hit key targets in a late-stage trial assessing its safety and efficacy in patients with chronic kidney disease (CKD) and type 2 diabetes.
Fast Track designation granted to chronic kidney disease treatment europeanpharmaceuticalreview
March 17, 2020
The US FDA has granted Fast Track designation to Jardiance® for the treatment of chronic kidney disease.
FDA Grants Fast Track Designation to Jardiance for Chronic Kidney Disease americanpharmaceuticalreview
March 16, 2020
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of Jardiance® (empagliflozin) to reduce the risk of kidney disease progression ...
AstraZeneca’s drug showed reduced Chronic Kidney Disease progress in cases of type-2 diabetes expresspharma
June 21, 2019
AstraZeneca has announced that a pre-specified exploratory analysis of renal data from the Phase III DECLARE-TIMI 58 trial, the broadest cardiovascular outcomes trial of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has shown that Forxiga (dapaglif
Cipla to launch cinacalcet hydrochloride tablets in US financialexpress
March 06, 2019
Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis.
Reata’s bardoxolone hits goals in phase 2 kidney disease trial fiercebiotech
September 27, 2018
Shares in Reata rose 12% in premarket trading.
US clears Pfizer’s biosimilar or Epogen, Procrit pharmatimes
July 13, 2018
The US Food and Drug Administration has approved Pfizer’s Retacrit, a biosimilar of Amgen's Epogen and Johnson & Johnson's Procrit.

Previous page 1 2 Next page